Usage Patterns and Incidence of Thyroid-related Adverse Events in Patients Treated with PD-1 Inhibitors |
Hwang, Seoyoung
(Chung-Ang University College of Pharmacy)
Kim, Heuijae (Chung-Ang University College of Pharmacy) Chung, Seonyoung (Pharmaceutical Department, Samsung Medical Center) Min, Myungsook (Pharmaceutical Department, Samsung Medical Center) Suh, Dong-Churl (Chung-Ang University College of Pharmacy) |
1 | Bristol Myers Squibb Corporation. OPDIVO® [package insert on the Internet]. Available from https://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed December 11, 2020. |
2 | Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017;377(19):1824-35. DOI |
3 | Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-cell lung cancer. N Engl J Med 2016;375(19):1823-33. DOI |
4 | Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 2018;360:k793. DOI |
5 | Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016;45:7-18. DOI |
6 | Sakakida T, Ishikawa T, Uchino J, et al. Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. Oncol Lett 2019;18(2):2140-7. |
7 | Costa R, Carneiro BA, Agulnik M, et al. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget 2017;8(5):8910-20. DOI |
8 | Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP. Incidence of thyroid function test abnormalities in patients receiving immunecheckpoint inhibitors for cancer treatment. Oncologist 2018;23(10):1236-41. DOI |
9 | Gohye Eoum, Yoonsook Cho, Sandy Jeong Rhie. Evaluation of nivolumab use and factors related to treatment outcomes in a cancer center of a top tier general hospital. Korean J Clin Pharm 2018;28(2):88-94. DOI |
10 | Gonzalez-Rodriguez E, Rodriguez-Abreu D. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 2016;21(7):804-16. DOI |
11 | Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015;372(26):2521-32. DOI |
12 | Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 2016;17(12):e542-e551. DOI |
13 | Health insurance review & assessment service. Question and answer for medical care application of immune checkpoint inhibitors, nivolumab and pembrolizumab. Available from https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030023080000&brdScnBltNo=4&brdBltNo=45624#none. Accessed December 11, 2020. |
14 | Morganstein DL, Lai Z, Diem S, et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 2017;86(4):614-20. DOI |
15 | Guaraldi F, Selva RL, Sama MT, et al. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Invest 2018;41(5):549-56. DOI |
16 | Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018;19(11):1480-92. DOI |
17 | Reck M, Schenker M, Lee KH, et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Eur J Cancer 2019;116:137-47. DOI |
18 | Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915-28. DOI |
19 | Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018;378(19):1789-801. DOI |
20 | Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM. Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol 2018;25(5):e403-e410. |
21 | de Filette J, Jansen Y, Schreuer M, et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 2016;101(11):4431-9. DOI |
22 | Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:190-209. DOI |
23 | Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 2017;28(3):583-9. DOI |
24 | Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw 2019;17(3):255-89. DOI |
25 | Ministry of Food and Drug Safety. OPDIVO® Intravenous injection (Nivolumab, recombinant). Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=201501485. Accessed December 11, 2020. |
26 | Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5(1):95. DOI |
27 | Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl_4):iv119-iv142. DOI |
28 | Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36(17):1714-68. DOI |
29 | Ministry of Food and Drug Safety. KEYTRUDA® Intravenous injection (Pembrolizumab, recombinant). Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=201501487. Accessed December 11, 2020. |
30 | U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Available from https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Accessed December 11, 2020. |
31 | Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372(4):320-30. DOI |
32 | Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019;20(10):1370-85. DOI |
33 | Duan J, Cui L, Zhao X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 Inhibitors in patients with cancer: A systematic review and metaanalysis. JAMA Oncol 2020;6(3):375-84. DOI |
34 | Merck, Sharp & Dohme Corporation. KEYTRUDA® [package insert on the Internet]. Available from https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Accessed December 11, 2020. |